Necroptosis suppresses inflammation via termination of TNF-or LPS-induced cytokine and chemokine production

Cell Death and Differentiation

Volumn 22, Issue 8, 2015, Pages 1313-1327

  Kearney, C J ^a   Cullen, S P ^a   Tynan, G A ^a   Henry, C M ^a   Clancy, D ^a   Lavelle, E C ^a   Martin, S J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL ADHESION MOLECULE; CHEMOKINE; CXCL1 CHEMOKINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE DERIVED CHEMOKINE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE; PROTEIN RIPK3; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; MLKL PROTEIN, HUMAN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPERNATANT; APOPTOSIS; CELL LINE; GENETICS; METABOLISM; PHYSIOLOGY;

APOPTOSIS; CELL LINE; CHEMOKINES; CYTOKINES; HUMANS; LIPOPOLYSACCHARIDES; PROTEIN KINASES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84935699564     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.222     Document Type: Article

References (69)

1. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-529.
2. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081-1086.
3. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-789.
4. Shore GC, Papa FR, Oakes SA. Signaling cell death from the endoplasmic reticulum stress response. Curr Opin Cell Biol 2011; 23: 143-149.
5. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011; 13: 184-190.
6. Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol 2012; 197: 857-867.
7. Matus S, Glimcher LH, Hetz C. Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Curr Opin Cell Biol 2011; 23: 239-252.
8. Cornejo VH, Hetz C. The unfolded protein response in Alzheimer's disease. Semin Immunopathol 2013; 35: 277-292.
9. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 2012; 13: 89-102.
10. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307: 935-939.
11. Tsaytler P, Harding HP, Ron D, Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 2011; 332: 91-94.
12. Okada T, Haze K, Nadanaka S, Yoshida H, Seidah NG, Hirano Y et al. A serine protease inhibitor prevents endoplasmic reticulum stress-induced cleavage but not transport of the membrane-bound transcription factor ATF6. J Biol Chem 2003; 278: 31024-31032.
13. Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011; 117: 1311-1314.
14. Mimura N, Fulciniti M, Gorgun G, Tai Y-T, Cirstea D, Santo L et al. Blockade of XBP1 splicing by inhibition of IRE1? is a promising therapeutic option in multiple myeloma. Blood 2012; 119: 5772-5781.
15. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin N Am 2005; 25: 451-468.
16. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol 1995; 17: 1-12.
17. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999; 43: 237-239.
18. Gündisch S, Boeckeler E, Behrends U, Amtmann E, Ehrhardt H, Jeremias I. Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res 2012; 32: 4251-4261.
19. Volden PA, Conzen SD. The influence of glucocorticoid signaling on tumor progression. Brain Behav Immun 2013; 30: S26-S31.
20. Herr I, Büchler MW, Mattern J. Glucocorticoid-mediated apoptosis resistance of solid tumors. Results Probl Cell Differ 2009; 49: 191-218.
21. Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A. Glucocorticoid receptor and breast cancer. Breast Cancer Res Treat 2011; 130: 1-10.
22. Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol 2013; 380: 32-40.
23. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007; 72: 799-809.
24. Song I-H, Gold R, Straub RH, Burmester G-R, Buttgereit F. New glucocorticoids on the horizon: repress, don't activate!. J Rheumatol 2005; 32: 1199-1207.
25. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
26. Schäcke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N et al. SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 2002; 40: 357-371.
27. Schäcke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007; 275: 109-117.
28. Zhang J-Z, Cavet ME, VanderMeid KR, Salvador-Silva M, López FJ, Ward KW. BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full antiinflammatory properties in human ocular cells. Mol Vis 2009; 15: 2606-2616.
29. Uings IJ, Needham D, Matthews J, Haase M, Austin R, Angell D et al. Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile. Br J Pharmacol 2013; 169: 1389-1403.
30. Cavet ME, Harrington KL, Ward KW, Zhang J-Z. Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis 2010; 16: 1791-1800.
31. Schäcke H, Zollner TM, Döcke WD, Rehwinkel H, Jaroch S, Skuballa W et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009; 158: 1088-1103.
32. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997; 48: 129-156.
33. Valotis A, Neukam K, Elert O, Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 2004; 93: 1337-1350.
34. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413: 739-743.
35. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 2011; 21: 961-966.
36. Richards P, Didszun C, Campesan S, Simpson A, Horley B, Young KW et al. Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ 2011; 18: 191-200.
37. Sajjad MU, Green EW, Miller-Fleming L, Hands S, Herrera F, Campesan S et al. DJ-1 modulates aggregation and pathogenesis in models of Huntington's disease. Hum Mol Genet 2013; 23: 755-766.
38. Green EW, Giorgini F. Choosing and using Drosophila models to characterize modifiers of Huntington's disease. Biochem Soc Trans 2012; 40: 739-745.
39. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 2003; 100: 5950-5955.
40. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
41. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol 2006; 5: 589-602.
42. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
43. Oliveira JMA. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J Neurochem 2010; 114: 1-12.
44. Hetz C, Glimcher LH. Protein homeostasis networks in physiology and disease. Curr Opin Cell Biol 2011; 23: 123-125.
45. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008; 5: 181-197.
46. Gow A, Wrabetz L. CHOP and the endoplasmic reticulum stress response in myelinating glia. Curr Opin Neurobiol 2009; 19: 505-510.
47. Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 2009; 23: 2294-2306.
48. Kouroku Y, Fujita E, Jimbo A, Kikuchi T, Yamagata T, Momoi MY et al. Polyglutamine aggregates stimulate ER stress signals and caspase-12 activation. Hum Mol Genet 2002; 11: 1505-1515.
49. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002; 16: 1345-1355.
50. Thomas M, Yu Z, Dadgar N, Varambally S, Yu J, Chinnaiyan AM et al. The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. J Biol Chem 2005; 280: 21264-21271.
51. Duennwald ML, Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 2008; 22: 3308-3319.
52. Cho KJ, Lee BI, Cheon SY, Kim HW, Kim HJ, Kim GW. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease. Neuroscience 2009; 163: 1128-1134.
53. Lee H, Noh J-Y, Oh Y, Kim Y, Chang J-W, Chung C-W et al. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux. Hum Mol Genet 2012; 21: 101-114.
54. Reijonen S, Putkonen N, Nørremølle A, Lindholm D, Korhonen L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp Cell Res 2008; 314: 950-960.
55. Jiang Y, Lv H, Liao M, Xu X, Huang S, Tan H et al. GRP78 counteracts cell death and protein aggregation caused by mutant huntingtin proteins. Neurosci Lett 2012; 516: 182-187.
56. Noh J-Y, Lee H, Song S, Kim NS, Im W, Kim M et al. SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition. J Biol Chem 2009; 284: 11318-11325.
57. Carnemolla A, Fossale E, Agostoni E, Michelazzi S, Calligaris R, De Maso L et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J Biol Chem 2009; 284: 18167-18173.
58. Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C et al. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy. Hum Mol Genet 2012; 21: 2245-2262.
59. Zuleta A, Vidal RL, Armentano D, Parsons G, Hetz C. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease. Biochem Biophys Res Commun 2012; 420: 558-563.
60. Rodriguez DA, Zamorano S, Lisbona F, Rojas-Rivera D, Urra H, Cubillos-Ruiz JR et al. BH3-only proteins are part of a regulatory network that control the sustained signaling of the unfolded protein response sensor IRE1. EMBO J 2012; 31: 2322-2335.
61. Aziz MH, Shen H, Maki CG. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase C. J Biol Chem2012; 287: 29825-29836.
62. Das I, Png CW, Oancea I, Hasnain SZ, Lourie R, Proctor M et al. Glucocorticoids alleviate intestinal ER stress by enhancing protein folding and degradation of misfolded proteins. J Exp Med 2013; 210: 1201-1216.
63. Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y et al. Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington's disease. Hum Mol Genet 2014; 23: 2737-2751.
64. Engel KB, Yamamoto KR. The glucocorticoid receptor and the coregulator Brm selectively modulate each other's occupancy and activity in a gene-specific manner. Mol Cell Biol 2011; 31: 3267-3276.
65. Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-? family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 2013; 24: 373-384.
66. Schindowski K, Bohlenund Halbach von O, Strelau J, Ridder DA, Herrmann O, Schober A et al. Regulation of GDF-15, a distant TGF-? superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res 2011; 343: 399-409.
67. Strelau J, Strzelczyk A, Rusu P, Bendner G, Wiese S, Diella F et al. Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci 2009; 29: 13640-13648.
68. Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ 2013; 20: 1475-1484.
69. Varadarajan S, Bampton ETW, Smalley JL, Tanaka K, Caves RE, Butterworth M et al. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ 2012; 19: 1896-1907.